HAMP and osteoporosis: We propose the development of next-generation iron chelators specifically targeting bone or the regulation of the hepcidin pathway to mitigate iron overload, thereby alleviating osteoporosis associated with ferroptosis and providing novel strategies for treating iron metabolism-related diseases.